ArticleFrontiers in endocrinology2025
The immune-related plasma protein LAT2 as a protective modulator in diabetic retinopathy: a Mendelian randomization study.
Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- In-depth analysis of retinal RNA transcriptome sequencing in a rat model of hypertensive retinopathy.Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Diabetic retinopathy (DR) is a leading cause of vision loss worldwide. Although numerous observational studies have explored candidate biomarkers, the causal contributions of circulating plasma proteins to DR pathogenesis remain largely unclear due to confounding and reverse causality. Methods: To address this, we performed a two-sample Mendelian randomization (MR) analysis using protein quantitative trait loci (pQTLs) derived from the UK Biobank Pharma Proteomics Project (n = 54,219) and DR outcome data from the FinnGen cohort (n = 96,429; 14,142 cases). Colocalization and transcriptome-based MR analyses were conducted to validate causal protein candidates. We further performed experimental validation in hyperglycemia-induced retinal cells and assessed immune mediation using MR-based mediation analysis. A phenome-wide MR (MR-PheWAS) was also conducted to evaluate disease specificity. Results: Among five significant proteins, we identified Linker for Activation of T Cells Family Member 2 (LAT2) as a robust protective factor for DR (OR = 0.358, 95% CI: 0.215-0.597, p < 0.001). Colocalization analysis (PP.H4 = 0.8546) and SMR analysis supported a shared genetic basis between LAT2 expression and DR. LAT2 expression was significantly upregulated under high-glucose stress in retinal cells. Mediation MR revealed that CD27 Conclusions: LAT2 may be a potential protective factor for diabetic retinopathy, offering preliminary insight for future biomarker development and prevention strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.